These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
160 related items for PubMed ID: 9620084
1. Influence of intravitreal injections of HPMPC and related nucleoside analogues on intraocular pressure in guinea pig eyes. Banker AS, De Clercq E, Taskintuna I, Keefe KS, Bergeron-Lynn G, Freeman WR. Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1233-42. PubMed ID: 9620084 [Abstract] [Full Text] [Related]
2. An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects. Taskintuna I, Banker AS, Rao NA, Wiley CA, Flores-Aguilar M, Munguia D, Bergeron-Lynn G, De Clercq E, Keefe K, Freeman WR. Exp Eye Res; 1997 May; 64(5):795-806. PubMed ID: 9245910 [Abstract] [Full Text] [Related]
3. Effects of topical and subconjunctival cidofovir (HPMPC) in an animal model. Banker AS, Bergeron-Lynn G, Keefe KS, De Clercq E, Taskintuna I, Freeman WR. Curr Eye Res; 1998 Jun; 17(6):560-6. PubMed ID: 9663845 [Abstract] [Full Text] [Related]
5. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Oncol Res; 1998 Jun; 10(10):523-31. PubMed ID: 10338155 [Abstract] [Full Text] [Related]
6. Intraocular properties of an alkoxyalkyl derivative of cyclic 9-(S)-(3-hydroxyl-2-phosphonomehoxypropyl) adenine, an intravitreally injectable anti-HCMV drug in rabbit and guinea pig. Tammewar AM, Cheng L, Hostetler KY, Falkenstein I, Beadle JR, Barron EC, Kozak I, Freeman WR. J Ocul Pharmacol Ther; 2007 Oct; 23(5):433-44. PubMed ID: 17900229 [Abstract] [Full Text] [Related]
7. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Li SB, Yang ZH, Feng JS, Fong CK, Lucia HL, Hsiung GD. Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690 [Abstract] [Full Text] [Related]
8. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Kirsch LS, Arevalo JF, Chavez de la Paz E, Munguia D, de Clercq E, Freeman WR. Ophthalmology; 1995 Apr; 102(4):533-42; discussion 542-3. PubMed ID: 7724170 [Abstract] [Full Text] [Related]
9. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Aduma P, Connelly MC, Srinivas RV, Fridland A. Mol Pharmacol; 1995 Apr; 47(4):816-22. PubMed ID: 7723743 [Abstract] [Full Text] [Related]
10. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Banker AS, Arevalo JF, Munguia D, Rahhal FM, Ishimoto B, Berry C, De Clercq E, Ochabski R, Taskintuna I, Freeman WR. Am J Ophthalmol; 1997 Aug; 124(2):168-80. PubMed ID: 9262540 [Abstract] [Full Text] [Related]
11. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity. Neyts J, De Clercq E. Verh K Acad Geneeskd Belg; 1994 Aug; 56(6):561-92. PubMed ID: 7892749 [Abstract] [Full Text] [Related]
12. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Reymen D, Naesens L, Balzarini J, Holý A, Dvoráková H, De Clercq E. Antiviral Res; 1995 Dec; 28(4):343-57. PubMed ID: 8669893 [Abstract] [Full Text] [Related]
13. Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine. Dolnak DR, Munguia D, Wiley CA, De Clercq E, Bergeron-Lynn GL, Boscher C, Connor JD, Sherwood C, Capparelli E, Armani R. Invest Ophthalmol Vis Sci; 1992 Apr; 33(5):1557-63. PubMed ID: 1559752 [Abstract] [Full Text] [Related]
14. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Cundy KC, Lynch G, Shaw JP, Hitchcock MJ, Lee WA. Curr Eye Res; 1996 May; 15(5):569-76. PubMed ID: 8670758 [Abstract] [Full Text] [Related]
15. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Neyts J, Snoeck R, Balzarini J, De Clercq E. Antiviral Res; 1991 Jul; 16(1):41-52. PubMed ID: 1663729 [Abstract] [Full Text] [Related]
16. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. Chavez-de la Paz E, Arevalo JF, Kirsch LS, Munguia D, Rahhal FM, De Clercq E, Freeman WR. Ophthalmology; 1997 Mar; 104(3):539-44. PubMed ID: 9082286 [Abstract] [Full Text] [Related]
17. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Keith KA, Hitchcock MJ, Lee WA, Holý A, Kern ER. Antimicrob Agents Chemother; 2003 Jul; 47(7):2193-8. PubMed ID: 12821467 [Abstract] [Full Text] [Related]
18. Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique. Snoeck R, Schols D, Andrei G, Neyts J, De Clercq E. Antiviral Res; 1991 Jul; 16(1):1-9. PubMed ID: 1663725 [Abstract] [Full Text] [Related]
19. Effect of partial retinal destruction and gliosis on the intravitreal pharmacokinetics of HPMPC. Kim JW, el-Haig W, Capparelli EV, Besen G, Connor JD, Freeman WR. Retina; 1995 Jul; 15(6):513-7. PubMed ID: 8747447 [Abstract] [Full Text] [Related]
20. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Taskintuna I, Rahhal FM, Rao NA, Wiley CA, Mueller AJ, Banker AS, De Clercq E, Arevalo JF, Freeman WR. Ophthalmology; 1997 Nov; 104(11):1827-36; discussion 1836-7. PubMed ID: 9373113 [Abstract] [Full Text] [Related] Page: [Next] [New Search]